Clinical trials: IBS, Diarrhea Predominant
Irritable Bowel Syndrome, Irritable Bowel Syndrome With Diarrhea (IBS-D)
Efficacy of Repeated Transcranial Magnetic Stimulation Combined With a Live Probiotic Tablet (Combined Bifidobacterium, Lactobacillus, Enterococcus and Bacillus Cereus Tablets, Live) in Diarrhea-Predominant Irritable Bowel Syndrome (IBS-D)
To evaluate the overall efficacy of repeated Transcranial Magnetic Stimulation(rTMS) combined with a Live Probiotic tablet (Combined Bifidobacterium, Lactobacillus, Enterococcus and Bacillus cereus Tablets, Live) in…
- Conditions
- Irritable Bowel Syndrome, Irritable Bowel Syndrome With Diarrhea (IBS-D), Repetitive Transcranial Magnetic Stimulation (rTMS), Probiotic
- Trial name
- NCT06960369
- Testing
- rTMS combined with Live Probiotic tablet
- Where
- China
- Volunteers
- 400 people, healthy volunteers welcome
- Sponsor
- The First Affiliated Hospital of Soochow University
Irritable Bowel Syndrome, Irritable Bowel Syndrome With Diarrhea (IBS-D)
Repeated Transcranial Magnetic Stimulation for the Treatment of Diarrhea-Predominant Irritable Bowel Syndrome: A Randomized Clinical Trial
Objectives: This study aims to evaluate the clinical efficacy and safety of repetitive transcranial magnetic stimulation (rTMS) in patients with diarrhea-predominant irritable bowel syndrome (IBS-D), and to explore the potential…
- Conditions
- Irritable Bowel Syndrome, Irritable Bowel Syndrome With Diarrhea (IBS-D), Repetitive Transcranial Magnetic Stimulation (rTMS), Chronic Diarrhea
- Trial name
- rTMS (NCT07581756)
- Testing
- rTMS group
- Where
- China
- Volunteers
- 46 people
- Sponsor
- The First Affiliated Hospital of Soochow University
Diarrhea-predominant Irritable Bowel Syndrome, Functional Diarrhea
Acupuncture for Patients With Diarrhea-predominant IBS or Functional Diarrhea: a Randomized Controlled Trial
This trial is to assess the effectiveness of three types of acupuncture for patients with functional diarrhea comparing to a positive drug control.
- Trial name
- NCT01350570
- Testing
- acupuncture, acupuncture group2, acupuncture group3
- Where
- China
- Volunteers
- 449 people
- Sponsor
- Chengdu University of Traditional Chinese Medicine
Irritable Bowel Syndrome
Efficacy, Safety, and Tolerability of Eluxadoline in the Treatment of Participants With Diarrhea-Predominant Irritable Bowel Syndrome (IBS-d)
The purpose of this study is to determine the efficacy, safety, and tolerability of different doses of eluxadoline (JNJ-27018966) compared with placebo in the treatment of participants with diarrhea-predominant irritable bowel…
- Trial name
- NCT01553747
- Testing
- Eluxadoline
- Where
- 253 sites in United States, Canada and 2 more
- Volunteers
- 1,146 people
- Sponsor
- Furiex Pharmaceuticals, Inc
Diarrhea-predominant Irritable Bowel Syndrome
Rifamycin SV-MMX® 600 mg Tablets Administered Three or Two Times Daily to Patients With IBS-D
The objective of this study is to evaluate the safety and efficacy Rifamycin SV-MMX® 600 mg tablets for patients with diarrhoea-predominant irritable bowel syndrome when administered two to three times daily.
- Trial name
- NCT03099785
- Testing
- Rifamycin SV 600mg t.i.d.
- Where
- 29 sites in Belgium, Germany and 2 more
- Volunteers
- 279 people
- Sponsor
- Cosmo Technologies Ltd
Diarrhoea Predominant Irritable Bowel Syndrome, IBS
Analyzing IBS to Identify Biomarkers and Microbiome Signatures
Microbiota from fecal samples from IBS-D patients, in combination with vitamin D supplementation added to our 3-D immunocompetent intestinal models will establish a high fidelity disease model to achieve our long-term goal to…
- Trial name
- NCT02419963
- Testing
- endoscopy for tissue biopsy, Blood Sample, Stool Sample
- Where
- United States
- Volunteers
- 26 people, healthy volunteers welcome
- Sponsor
- Mayo Clinic
IBS-D (Diarrhea-predominant)
Study to Evaluate the Treatment Benefits of Probiotic Clostridium Butyricum CBM588® for IBS-D
Irritable bowel syndrome (IBS) is a prevalent gastrointestinal disorder affecting 15-20% of people in industrialized countries, often presenting as abdominal discomfort, pain, and altered bowel habits, significantly impacting…
- Trial name
- PROREDI (NCT06676514)
- Testing
- Probiotic Clostridium butyricum CBM588®, Standard of care IBS-D treatment
- Where
- Italy
- Volunteers
- 405 people
- Sponsor
- Liaquat University of Medical & Health Sciences
Irritable Bowel Syndrome, Irritable Bowel Syndrome With Diarrhea
Hydrogen Breath Test an Instrument to Predict Rifaximin-Response in Irritable Bowel Syndrome Predominant Diarrhea
The purpose of this study is to learn more about how to improve treatment of patients with diarrhea predominant Irritable Bowel Syndrome (IBS-D) symptoms.Included patients will be requested to answer online surveys and will…
- Trial name
- NCT03729271
- Testing
- Rifaximin, Glucose and lactulose hydrogen breath testing
- Where
- United States
- Volunteers
- 148 people
- Sponsor
- University of Michigan
Diarrhea-predominant Irritable Bowel Syndrome
A Study to Assess the Efficacy and Safety of YM060 in Female Patients With Diarrhea-predominant Irritable Bowel Syndrome (IBS)
To demonstrate the superiority of YM060 to a placebo in global assessment of relief of overall IBS symptoms and stool form normalization, and to evaluate safety in female patients with diarrhea-predominant irritable bowel…
- Trial name
- NCT01870895
- Testing
- YM060
- Where
- 4 sites in Japan
- Volunteers
- 577 people
- Sponsor
- Astellas Pharma Inc
Diarrhea Predominant Irritable Bowel Syndrome, Small Intestinal Bacterial Overgrowth
Use of SBI in IBS Subjects Following a Successful Treatment of Small Intestinal Bacterial Overgrowth
The primary objective of this study is to determine whether giving SBI as a medical food starting with maintenance of health in the management of chronic loose and frequent stools in IBS-D subjects with SIBO after successful…
- Trial name
- NCT02251483
- Testing
- Serum-derived bovine immunoglobulin protein isolate (SBI)
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- Cedars-Sinai Medical Center
Irritable Colon
Study to Assess the Effect Of Alosetron On Mucosal Blood Flow
This study will look at colonic mucosal blood flow in subjects who have taken alosetron vs placebo and healthy volunteers vs diarrhea-predominant Irritable Bowel Syndrome (d-IBS) patients.
- Trial name
- NCT00370032
- Testing
- alosetron
- Where
- United Kingdom
- Volunteers
- 49 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Irritable Bowel Syndrome
Phase 3 Study of YM060 in Patients With Diarrhea-predominant Irritable Bowel Syndrome (d-IBS)
This study will examine the efficacy, safety and tolerability of oral dose of YM060, 5-HT3 receptor antagonist, in patients with d-IBS.
- Trial name
- NCT00189696
- Testing
- YM060
- Where
- 4 sites in Japan
- Sponsor
- Astellas Pharma Inc
Diarrhoea Predominant Irritable Bowel Syndrome
Retrospective Study of IBS-D Patients Previously Receiving SBI
This is a retrospective study designed to gather outcomes data from existing medical charts from patients who have taken EnteraGam for management of their IBS-D for at least eight weeks.
- Trial name
- NCT02661425
- Testing
- EnteraGam
- Where
- 16 sites in United States
- Volunteers
- 165 people
- Sponsor
- Entera Health, Inc
IBS, Diarrhea Predominant, IBS, Constipation Predominant
Proposal Evaluating Time-specific Relationships Between Variables of Pain, Stress, and Bloating in IBS Diarrhea and Constipation Symptoms Using a Palm Pilot
Purpose: The associations between pain, stress, bloating, and their short interval temporal relationships to defecation in IBS D, C \& M are of great interest to the field of functional GI disorders, but have not been adequately…
- Conditions
- IBS, Diarrhea Predominant, IBS, Constipation Predominant, IBS, Mixed Symptoms
- Trial name
- NCT00619125
- Testing
- palm pilot recording responses to questionnaires
- Volunteers
- 85 people, healthy volunteers welcome
- Sponsor
- University of North Carolina, Chapel Hill
Irritable Bowel Syndrome With Diarrhea
Evaluating the Safety and Efficacy of the Probiotic Bifidobacterium Longum ES1 and the Post Biotic Heat-treated Bifidobacterium Longum ES1 (HT-ES1) on IBS Symptom Severity in Patients With Diarrhoea Predominant Irritable Bowel Syndrome
Randomized controlled clinical study has been proposed to evaluate the safety and efficacy of ES1 probiotic strain and heat-treated ES1 postbiotic strain in individuals suffering from IBS-D.
- Trial name
- NCT05339243
- Testing
- ES 1, HT ES1
- Where
- 8 sites in India
- Volunteers
- 200 people
- Sponsor
- Vedic Lifesciences Pvt. Ltd.
Irritable Bowel Syndrome
A Multi-Center Trial to Determine the Safety and Efficacy of LX1033 in Subjects With Diarrhea-Predominant Irritable Bowel Syndrome
The objective of this study is to evaluate the safety and efficacy of LX1033 over a range of dose levels in subjects with diarrhea-predominant Irritable Bowel Syndrome (IBS).
- Trial name
- NCT01494233
- Testing
- 250 mg LX1033 tablets
- Where
- 81 sites in United States
- Volunteers
- 373 people
- Sponsor
- Lexicon Pharmaceuticals
Irritable Bowel Syndrome
A Study of YM060 in Diarrhea-predominant Irritable Bowel Syndrome (d-IBS)
This study will examine the efficacy, safety and tolerability of different oral dose of YM060, 5-HT3 receptor antagonist, in patients with d-IBS.
- Trial name
- NCT00189813
- Testing
- YM060
- Where
- 45 sites in Bulgaria, Czechia and 6 more
- Volunteers
- 691 people
- Sponsor
- Astellas Pharma Inc
Diarrhea-predominant Irritable Bowel Syndrome
Allogeneic Microbiota-reconstitution (AMR) in Diarrhea-predominant Irritable Bowel Syndrome (IBS-D)
The investigators will perform a multicenter, 2:1 randomized, double-blinded, placebo-controlled trial of AMR in patients with diarrhea predominant-IBS (IBS-D) diagnosed according to Rome III criteria and the IBS-QOL…
- Trial name
- AMIRA (NCT04095988)
- Testing
- Allogeneic microbiota reconstitution
- Where
- 2 sites in Germany
- Volunteers
- 42 people
- Sponsor
- University of Ulm
Irritable Bowel Syndrome
Efficacy, Safety, and Tolerability of Eluxadoline in the Treatment of Participants With Diarrhea-Predominant Irritable Bowel Syndrome (IBS-d)
The purpose of this study is to determine the efficacy, safety, and tolerability of different doses of eluxadoline (JNJ-27018966) compared with placebo in the treatment of participants with diarrhea-predominant irritable bowel…
- Trial name
- NCT01553591
- Testing
- Eluxadoline
- Where
- 283 sites in United States, Canada and 1 more
- Volunteers
- 1,282 people
- Sponsor
- Furiex Pharmaceuticals, Inc
IBS-D and Functional Dyspepsia
Trenev Trio/Healthy Trinity for Symptoms of Diarrhea-predominant Irritable Bowel Syndrome (IBS) and Functional Dyspepsia
Primary Objective: To confirm the efficacy of the probiotic product Healthy Trinity (retail label)/Trenev Trio (professional label) in the improvement of symptoms in adult patients with diarrhea-predominant irritable bowel…
- Trial name
- NCT01268618
- Testing
- Probiotic
- Where
- 2 sites in United States
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Sprim Advanced Life Sciences